glofitamab   Click here for help

GtoPdb Ligand ID: 12758

Synonyms: CD20-TCB (2:1) | Columvi® | glofitamab-gxbm | RG-6026 | RG6026
Approved drug
glofitamab is an approved drug (FDA & EMA (2023))
Compound class: Antibody
Comment: Glofitamab (RG6026) is a bispecific antibody that concomitantly binds to CD20 (on malignant B cells) and CD3ε (on T cells) [1-2]. It was designed to promote T cell-mediated killing of B cell lymphomas [3,5]. It is bivalent for CD20 and monovalent for CD3ε and has an extended circulatory half-life compared to obinutuzumab.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V et al.. (2018)
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.
Clin Cancer Res, 24 (19): 4785-4797. [PMID:29716920]
2. Cremasco F, Menietti E, Speziale D, Sam J, Sammicheli S, Richard M, Varol A, Klein C, Umana P, Bacac M et al.. (2021)
Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model.
PLoS One, 16 (1): e0241091. [PMID:33406104]
3. Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, Khan C, Wróbel T, Offner F, Trněný M et al.. (2022)
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med, 387 (24): 2220-2231. [PMID:36507690]
4. Shirley M. (2023)
Glofitamab: First Approval.
Drugs, 83 (10): 935-941. [PMID:37285013]
5. Wang C, Liu Y. (2023)
Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting.
J Hematol Oncol, 16 (1): 20. [PMID:36895020]